This week, we addressed some of the barriers that patients face when it comes to their health and how the biopharmaceutical industry helps individuals get the treatments they need.
Most Recent Posts
A new story from the AP today, “Patient advocates say insurers avoiding the sick,” highlights the growing concern among patients and insurance commissioners about high cost-sharing for medicines in the new health insurance exchanges.
The science of informatics drives innovation that is defining future approaches to information and knowledge management in biomedical research, clinical care, and public health.
A new PhRMA survey found that Americans are paying more attention to their health, and, thanks to the countless resources at our fingertips, information is often just a click away. Easy access to vast amounts of information, however, has led to misconceptions about what is and isn’t healthy. Today, for example, just 33 percent of Americans believe it is very easy to get accurate and complete health care information.
Pharmaceutics is that area of biomedical and pharmaceutical sciences that deals with drug delivery systems, in particular the design and evaluation of contemporary pharmaceutical dosage forms so that they are safe, effective, and reliable.
“Despite rigorous and extensive testing for safety and efficacy, a single piece of widely circulated false information can have lasting impact on the public’s perception on vaccine safety.” This month is National Immunization Awareness Month, and as children go back to school, this comment by Conversations contributor Roberta DeBiasi of the Child
This week we released From Hope to Cures: PhRMA’s Second Annual National Health Survey revealing new data on how Americans view their own health as well as that of the Nation. The survey also reveals three new trends that appear to be evolving under the shifting health care landscape.
How we can further improve patients’ lives? This is a question the biopharmaceutical industry is constantly asking. This week on the Catalyst we noted that one way to achieve this is by supporting ways to ensure patients receive, and benefit from treatments.
A national dialogue is needed around the value of new medicines and cures and the role they play in improving patient health and helping to manage long-term spending in the U.S. health care system. Unfortunately, the debate around hepatitis C has, for the most part, been twisted to the point that modern-day cures are seen as a nuisance rather than a monumental step forward in the battle against disease. (This post was updated on August 5, 2014.)
For many patients, hope for a brighter future is directly tied to the potential of medicines in the pipeline to treat their disease or condition.
Today, more than 52 million Americans are affected by arthritis and related musculoskeletal diseases, consisting of more than 100 different conditions, according to the U.S. Centers for Disease Control and Prevention (CDC). The CDC projects prevalence of musculoskeletal diseases could increase to 67 million by 2030 if current trends continue.
Medicare Part D continues to be a success for beneficiaries.
This week was packed with lively and informative discussions surrounding the incredibly important issue of treatment costs and the need to incorporate value into the cost narrative.